stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Current ratio
Ascendis Pharma A/S's current ratio at the end of the quarter to 30 June 2026 was 3.0×, up 2.0× from fiscal 2025 (1.0×). Over the past ten years it has ranged from 1.0× (fiscal 2025) to 14.0× (fiscal 2020) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 4.9× and in line with the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.0× | (11.25%) |
| FY2024 | 1.2× | (67.19%) |
| FY2023 | 3.6× | (33.96%) |
| FY2022 | 5.4× | (32.86%) |
| FY2021 | 8.0× | (42.71%) |
| FY2020 | 14.0× | 10.06% |
| FY2019 | 12.7× | 69.21% |
| FY2018 | 7.5× | (12.58%) |
| FY2017 | 8.6× | (37.01%) |
| FY2016 | 13.7× | 24.50% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 3.0× | 200.26% |
| Mar 2026 | 1.0× | (3.94%) |
| Dec 2025 | 1.0× | 0.51% |
| Sep 2025 | 1.0× | 1.23% |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 8.6× |
| SMMT Summit Therapeutics PLC compare | 7.0× |
| HALO Halozyme Therapeutics, Inc. compare | 3.9× |
| EXEL Exelixis, Inc. compare | 3.2× |
| ASND Ascendis Pharma A/S | 3.0× |
| INSM Insmed, Inc. compare | 2.9× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 2.5× |
| BBIO BridgeBio Pharma, Inc. compare | 2.1× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement